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Abstract
Background: Survival advantage following trans-arterial chemoembolization (TACE) is variable in patients with
hepatocellular carcinoma (HCC). We combined pre-TACE radiologic features to derive a novel prognostic signature
in HCC.
Methods: A multi-institutional dataset of 98 patients was generated from two retrospective cohorts from United
Kingdom (65%) and Italy (36%). The prognostic impact of a number baseline imaging parameters was assessed and
factors significant on univariate analysis were combined to create a novel radiologic signature on multivariable
analyses predictive of overall survival (OS) following TACE.
Results: Median OS was 15.4 months. Tumour size > 7 cm (p < 0.001), intra-tumour necrosis (ITN) (p = 0.02) and
arterial ectatic neovascularisation (AEN) (p = 0.03) emerged as individual prognostic factors together with radiologic
response (p < 0.001) and elevated alpha-fetoprotein (AFP) (p = 0.01). Combination of tumour size > 7 cm, ITN and
AEN identified patients with poor prognosis (p < 0.001).
Conclusions: We identified a coherent signature based on commonly available imaging biomarkers likely to be
reflective of differential patterns of relative hypoxia and neovascularisation. Large tumours displaying AEN and ITN
are characterised by a shorter survival after TACE.
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Background
Trans-arterial chemo-embolisation (TACE) is universally
recognised as a suitable therapy to improve the survival
of patients with hepatocellular carcinoma (HCC) who
cluster into the “intermediate” Barcelona Clinic Liver
Cancer (BCLC) stage [1].
Heterogeneity in survival is nonetheless wide and origi-
nates from numerous patient as well as treatment-related
factors [2]. In clinical practice TACE is often performed
sequentially until technically feasible and/or extra-hepatic
or portal vein invasion (PVI) develops [3]. The lack of
shared criteria to define chemoembolization failure,
however, makes it difficult for clinicians to estimate
long-term benefits from repeated loco-regional treat-
ments, a point of major concern due to the significant
rate of morbidity and mortality attributable to TACE in
a palliative population [4].
It is felt that TACE might be futile in a proportion of
patients displaying adverse prognostic features, a con-
cept that has led to the qualification of novel prognostic
algorithms in this population [5], none of which has
however entered the clinic due to concerns over external
validity [6].
Quantification of tumour burden and PVI are central
elements of most HCC staging systems [7]. Additional
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imaging features of HCC reflecting vascularity and
growth pattern have been investigated as biomarkers to
further characterise the tumour phenotype [8].
In our research of novel prognostic markers in TACE
candidates we focused on a number of imaging bio-
markers reflecting tumour hypoxia-neovascularisation
due to their potential impact on the penetration of cyto-
toxics and post-embolisation ischaemia, with implica-
tions in treatment efficacy and patients’ survival. These
radiologic parameters include the presence of arterial
ectatic neovascularisation (AEN), peri-tumour capsule
(PTC), intra-tumour necrosis (ITN) and artero-venous
shunting (AVS). In this pilot study we show that that the
presence of ITN, AVS and tumour size predict response
to TACE. Moreover, we derived a novel prognostic sig-
nature that can be utilized in routine clinical practice to
optimise the provision of TACE.
Methods
Patients
We conducted a retrospective, multi-institutional study
of 98 consecutive patients with a diagnosis of HCC, in-
cluding 64 treated with conventional TACE at Imperial
College, London (UK) between 2001 and 2012 and a sec-
ond subgroup of 34 patients from Novara (Italy), treated
between 2004 and 2013 (Table 1). In both centers TACE
consisted of intrarterial infusion of doxorubicin emulsi-
fied in lipiodol followed by embolisation with gelatin
sponge particles.
All patients underwent a tri-phasic computer tomog-
raphy (CT) scan prior to and 6–8 weeks following TACE.
A team of hepato-biliary radiologists (P.T. and M.P.) and
HPB surgeons (M.P., I.R. and A.G.) blinded to treatment
outcome reviewed CT and pre-treatment angiogram im-
ages with concordance reached over the qualification of
each radiologic feature. Restaging followed modified
RECIST (mRECIST) criteria [9]. However, to account for
the presence of multiple of multiple lesions being treated
within the liver, both targeted and overall imaging re-
sponses were assessed. The following radiologic features
were evaluated for prognostic significance: size of domin-
ant nodule during arterial enhancement, presence of PTC
[10] and ITN if the fraction of tumour lacking arterial en-
hancement was > 50%. A qualitative analysis of the intra-
tumour vascular architecture was performed on arterial
CT sequences and matched hepatic arterial angiogram
noting the presence of a clear vascular enhancement evi-
denced by abnormal ectatic vessels running a tortuous
course within the tumour mass. The angiographic pres-
ence of AVS was defined by arterial to venous contrast ex-
travasation during the arterial phase with a subsequent
retained enhancement during the portal and late venous
phase. Examples of each radiologic feature are shown
(Fig. 1a-f). Assessments of radiologic features were
performed on baseline scans. Overall survival (OS) was
calculated from initial TACE to the time of death or last-
documented follow-up. The local Research Ethics Com-
mittee, Imperial College Healthcare NHS Trust, approved
the study.
Statistical analysis
Pearson χ2-square test and analysis of variance were
used to determine any associations between the response
to TACE and variables of interest. Kaplan-Meier statis-
tics followed by stepwise backward Cox regression was
used for uni- and multivariable analyses of survival. A
combined score was derived from the combination of
radiologic traits independently associated with patient’s
survival based on multivariate Cox regression. All statis-
tical analysis was conducted using SPSS statistical pack-
age version 22 (SPSS Inc., Chicago, IL, USA). Variables
with a p-value greater than 0.10 were removed from the
Cox regression model. For all other analyses a signifi-
cance level of 0.05 was adopted.
Results
Demographics
The pre-treatment clinico-pathologic features of the 98
patients identified are reported in Table 1. Most patients
were within BCLC-B stage (88%) and Child-Pugh A class
(77%). Median age was 64 years (range 33–82), with al-
cohol excess (39%) and hepatitis C infection (33%) being
the most prevalent aetiologies. The majority of patients
received TACE as first treatment for HCC (79%), and
66% (n = 65) underwent > 1 TACE. In the Hammersmith
Hospital cohort 29 from 69 patients (42%) had systemic
therapy following TACE. In the majority this consisted
of sorafenib (35%) whilst the rest were treated on clinical
trial or with chemotherapy. Similarly, 15 patients from
the Italian cohort (44%) received sorafenib after TACE.
the majority of patients to dominant lesion treated were
< 7 cm (72%) with median size of 4.1 cm (range 1–
18 cm). When considering the radiologic parameters of
interest, nine patients (10%) had tumours displaying >
50% of necrosis, whilst PTC was detected in 17% (n =
17). AVS was evident in 49% of patients (n = 48), whilst
AEN was found in 88% (n = 88). Eleven patients (11%)
had segmental PVI.
Radiologic parameters as predictors of treatment
response
After the first TACE session, 15 (15%) patients experi-
enced a complete response to therapy, 28 (39%) had par-
tial response, 36 (37%) had stable disease and 7 (7%) had
progressive disease according to mRECIST. Response
data was not available for 12 patients; one patient died
prior to assessment, one underwent transplantation
prior to assessment and the remaining 10 were lost to
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follow-up. In terms of radiological parameters predictive
of treatment outcome, a trend was observed between
the presence of ITN and poor response to therapy (p =
0.08). No other radiologic parameter of interest corre-
lated with treatment response. Tumour size less than
7 cm (p = 0.03) and serum alpha-fetoprotein (AFP) <
400 ng/ml (p = 0.02) both correlated with improved re-
sponse with TACE imaging most likely as a reflection of
low tumour burden.
Radiologic parameters as predictors of overall survival
The median follow-up period after TACE was 11 months
(2.4–96 months). The OS was 15.4 months (range 2–
96 months) with a total of 59 recorded deaths (60%) at
the time of censoring. As reported in Table 2, tumour
size > 7 cm (p < 0.001), presence of AEN (p = 0.03), ITN
(p = 0.02), AFP > 400 ng/ml (p = 0.01) and radiologic re-
sponse (p < 0.001) were found to be prognostic on uni-
variate analysis. Neither PTC nor AVS influenced
patients’ prognosis. Multivariate analysis identified both
the presence of AEN (HR- hazard ratio 4.1 95% CI-
confidence interval 1.0–16.5, p = 0.04) and radiologic re-
sponse to initial TACE (HR 0.5 95% CI 0.3–0.8, p = 0.01)
as significant independent predictors of OS in HCC. A
combined prognostic score using both AEN and radio-
logic response was then derived using logistic regression
to determine the predicted probability of death.
Table 1 Demographic and clinical characteristics of patients
with HCC treated with TACE
Baseline characteristic n = 98, (%) or median, (range)
Age, years 71 (33–84)
Gender
Male 76 (78)
Female 22 (25)
Risk factors for Chronic Liver Disease
Hepatitis C Virus infection 32 (33)
Hepatitis B Virus Infection 12 (12)
Ethanol Excess 38 (39)
Others 9 (9)
Unknown 8 (8)
Child Turcotte Pugh Class
A 76 (77)
B 22 (23)
BCLC Stage
A 10 (10)
B 77 (78)
C 11 (11)
Number of Nodules
1–2 77 (79)
> 2 21 (21)
Maximum tumour diameter
≤ 7 cm 71 (72)
> 7 cm 27 (28)
Portal vein invasion (PVI)
Absent 87 (89)
Present 11 (11)
Albumin, g/L 33 (14–47)
Total bilirubin, umol/L 17 (4–124)
ALT, IU/L 44 (10–348)
AST, IU/L 59 (20–999)
ALP, IU/L 207 (62–680)
AFP, ng/ml 45 (2–130.000)
INR 1.1 (1.0–1.4)
Platelet Count, × 109/L 133 (46–444)
Number of TACE procedures
1 33 (34)
2 33 (34)
≥ 3 32 (32)
Prior Treatments
First line TACE 78 (79)
Resection 7 (6)
Transplantation 1 (1)
Radiofrequency ablation 22 (14)
Table 1 Demographic and clinical characteristics of patients
with HCC treated with TACE (Continued)
Baseline characteristic n = 98, (%) or median, (range)
Modified RECIST response following TACE
Complete Response 15 (15)
Partial Response 28 (29)
Stable Disease 36 (37)
Progressive Disease 7 (7)
Missing 12 (12)
Peri-tumoural capsule (PTC)
Absent 81 (83)
Present 17 (17)
Ectatic arterial neovascularization (EAN)
Absent 10 (10)
Present 88 (88)
Artero-venous shunting (AVS)
Absent 47 (48)
Present 48 (49)
Not assessable 3 (3)
Intra-tumour necrosis (ITN)
< 50% 89 (90)
> 50% 9 (10)
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Assessment of a novel radiologic prognostic signature
Based on the results of the multivariate analysis we de-
rived a compound signature inclusive of tumour size,
ITN and AEN, combined with equal weighting (Table 3)
and tested this signature for its independent prognostic
value in a multivariable Cox regression model including
radiologic response and baseline AFP levels. This con-
firmed mRECIST response (HR 1.9, 95%CI 1.3–2.7, p <
0.001) and the radiologic signature (HR 2.0, 95%CI 1.3–
2.9, p < 0.001) as independent predictors of OS.
According to baseline prognostic features, nine pa-
tients (10%) had 1 adverse factor, whilst 61 (62%) had 2,
21 (21%) had 3 and 7 (7%) had 4. Median OS was not
reached in patients with 1 adverse factor, whilst equaled
17.6 months (range 13–21 months) for patients with 2
factors, deteriorating to 9.4 (3.7–15.0) and 7.4 months
(5–9.7) for patients with 3 and 4 factors respectively (p
< 0.001). To facilitate clinical applicability we dichoto-
mised patients as high versus low-risk depending on the
presence of ≥ 2 adverse features. Low-risk patients had a
median OS of 18 months (range 15–21), deteriorating to
8.8 months (4.7–13) in high-risk patients (HR 2.6,
95%CI 1.4–4.4, p < 0.001). Low-risk patients had a higher
proportion of complete and partial responses following
TACE (100 and 71%) compared to high-risk (0 and 29%,
χ2p = 0.01) (Fig. 2).
Discussion
Following decades of improvements in the administra-
tion of TACE, research efforts are now concentrated at a
more comprehensive clinical phenotyping of patients
with intermediate-stage HCC in order to improve pa-
tient selection, maximise survival outcomes and prevent
iatrogenic morbidity [11].
Our multi-institutional, preliminary study focused
upon distinctive radiologic features that are biologically
linked to HCC progression through hypoxia and neo-
angiogenesis to derive a clinically applicable signature
capable of predicting survival advantage after initial
TACE.
We demonstrated that patients with tumours > 7 cm,
presence of ITN and AEN have a similar outlook to un-
treated patients with advanced HCC [12], to suggest that
TACE-induced survival benefit might have been very
small in patients harboring a poor prognostic signature.
Interestingly, patients with good prognosis had a
higher proportion of objective radiologic responses to
TACE, confirming the ability of the signature to detect a
patient subgroup where treatment was more efficacious
as a likely result of lower tumour burden and possibly
better arterial perfusion of the target lesions.
Importantly, multivariable analysis confirmed the sur-
vival advantage identified by the newly qualified signa-
ture as independent from other common clinico-
pathologic variables including baseline AFP levels and
radiologic response.
The prospect of predicting long-term outcomes fol-
lowing TACE based on pre-treatment radiologic features
of the tumour is not a novel concept in HCC [13]. How-
ever this is the first study to comprehensively evaluate
Fig. 1 Representative triphasic CT sequences of imaging biomarkers are illustrated: intra-tumour necrosis (ITN) (a), presence of peri-tumour cap-
sule (PTC) (b), tumour size >7cm with portal vein involvement (PVI) (c), arterial ectatic neovascularisation (AEN) (d) and artero-venous shunting
(AVS) identified on a pre-treatment hepatic arterial angiogram (e)
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radiologic predictors relating to hypoxia and neo-
angiogenesis on routine diagnostic CT scans without the
need to extrapolate complex perfusion parameters [14].
Robust evidence suggests that the natural progression of
HCC is highly reliant on hypoxia and neo-angiogenesis,
both recognised as adverse prognostic domains [15] and
therapeutic targets [16]. The reducing oxygen tension that
characterizes larger and highly proliferating tumours is
the main trigger to hypoxia-inducible factors expression,
which leads to the progressive neo-arterialization of nas-
cent HCC nodules through the sustained release of pro-
angiogenic factors [17].
Newly formed vasculature demonstrates increased per-
meability, tortuous course and wider luminal diameters
Table 2 Univariate analysis of prognostic factors of overall survival
UNIVARIATE ANALYSIS MULTIVARIATE ANALYSIS
Variable N = 98 (%) Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value
Tumour size
< 7 cm 23 (36) 2.8 (1.6–5.0) < 0.001
> 7 cm 28 (44)
Number of nodules
< 2 77 (79) – NS
≥ 2 21 (21)
AFP, ng/ml
< 400 83 (85) 2.2 (1.2–4.2) 0.01
≥ 400 15 (15)
Peri-tumoural Capsule (PTC)
Absent 81 (83) – NS
Present 17 (17)
Ectatic Arterial Neovascularsation (EAN)
Absent 10 (10) 4.1 (1.0–8.0) 0.03 4.1 (1.0–16.5) 0.04
Present 88 (88)
Artero-venous shunting (AVS)
Absent 47 (48) – NS
Present 48 (49)
Intra-tumour necrosis (ITN)
< 50% 89 (90) 2.2 (1.1–4.6) 0.02
≥ 50% 9 (10)
Portal vein invasion (PVI)
Absent 10 (10) – NS
Present 88 (88)
Child Pugh class
A 76 (77) – NS
B 22 (23)
BCLC Stage
A 10 (10) – NS
B 77 (78)
C 11 (11)
Radiologic Response
CR 15 (15) 2.0 (1.4–2.9) < 0.001 0.5 (0.3–0.8) 0.01
PR 28 (29)
SD 36 (37)
PD 7 (7)
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compared to normal vessels, which can be easily de-
tected on arterial CT sequences [14], often in form of
aberrant AV shunting [18]. The emergence of ITN is an
equally common finding in HCC and a surrogate marker
of highly proliferating tumours that fail to maintain the
required nutrient and oxygen supply [19]. In our study,
AEN and ITN were the only hypoxia-related radiologic
traits to display a significant association with patients’
survival, together with tumour size [20].
However, we could not reproduce a prognostic role for
segmental PVI or PTC. In a recently published Korean
study on 88 patients with prevalently hepatitis B virus
related HCC (62%) PVI, major bile ducts invasion and
tumour margin irregularity predicted for poorer survival
and response to initial TACE [8]. It is documented that
survival of patients with small intrahepatic PVI is similar
to patients with liver-confined HCC, qualifying them as
candidates for TACE [21]. Whilst no information on the
extent of PVI is given in the Korean study [8], it is likely
that the enriched proportion of patients with limited
PVI has contributed to its lack of prognostic significance
in our study.
Despite the relatively limited sample size, the multi-
center nature of our study supports the significance of
our findings, reducing the chances of selection bias
stemming from single-institution experience. Central re-
view of diagnostic scans also guarantees for homogeneity
and reproducibility in the qualification of imaging bio-
markers. Whilst provocative the results of this study re-
quire external validation in a large population group
with a focus on Eastern patients, where disease aetiology
and management differ significantly from Western coun-
tries. Another limitation of our study stems from the use
of OS, a composite end-point in HCC stemming from
the severity of underlying liver disease and cancer
Table 3 Prognostic factor composing the novel hypoxia-based
radiologic signature
Radiologic Feature Score
Dominant tumour size
< 7 cm 0
≥ 7 cm 1
Arterial ectatic neovascularization
Absent 0
Present 1
Intra-tumour necrosis
Absent 0
Present 1
Good Prognosis: total score 0–1
Poor Prognosis: total score ≥ 2
Fig. 2 Kaplan-Meier curves showing the relationship between overall survival and the newly qualified radiologic signature in patients treated
with TACE
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progression. OS is also influenced by post-TACE treat-
ment, which however was relatively well balanced across
both sub-cohorts. Whilst it could be argued that OS re-
mains the most clinically meaningful endpoint in the
management of HCC, the impact of this signature on
the progression free survival, a frequently used surrogate
of OS in clinical trials, would also be important to ex-
pand the translational relevance of our newly qualified
prognostic algorithm.
Lastly, a comparative assessment of the radiologic sig-
nature with other emerging prognostic models in
intermediate-stage HCC would be beneficial to truly ap-
preciate its clinical utility, a task that should be explored
in adequately powered, multicenter case series [11].
Conclusions
To conclude, our study preliminarily qualifies a novel
hypoxic-driven signature based on simple and readily ac-
cessible radiologic features of HCC including tumour
size, AEN and ITN. Given the strong linkage of each
biomarker to the biologic foundations of HCC progres-
sion, their potential to stratify patients with a 10 months
OS difference is not surprising and warrants clinical
translation following adequate validation studies. The
prognostic relationship with hypoxia and angiogenesis
qualifies this signature as a potential stratifying bio-
marker to optimise therapy, a strategy that should be
validated in future studies.
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